Leukemia, Myeloid, Acute
Conditions
Keywords
Acute Myeloid Leukemia (AML)
Brief summary
Among patients with a diagnosis of AML who received non-intensive chemotherapy: * Describe patient demographic and clinical characteristics * Describe treatment patterns * Describe effectiveness outcomes * Evaluate tumor response
Interventions
DRUGazacitidine
Patients taking azacitidine
DRUGvenetoclax
patients taking venetoclax
DRUGglasdegib
patients taking glasdegib
Sponsors
Pfizer
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Patients must meet all of the following inclusion criteria to be eligible for inclusion in the study: 1. Confirmed diagnosis of AML on or after 01 January 2012 through Clinical Research Nurse (CRN) review of provider documentation of AML diagnosis in the medical record. 2. Receipt of non-intensive therapy at any point during first line therapy following initial AML diagnosis. For this study, non-intensive therapy will be defined as 1 of the following agents, alone or in combination with any other agent: 1. AZA 2. GLAS 3. VEN 3. Age ≥18 years at initial diagnosis of AML.
Exclusion criteria
Patients meeting any of the following criteria will not be included in the study: 1\. Record of 1 or more of the following confounding diagnoses at any point before or after AML diagnosis: Acute lymphoblastic leukemia; acute promyelocytic leukemia, aggressive systemic mastocytosis; hypereosinophilic syndrome and/or chronic eosinophilic leukemia; dermatofibrosarcoma protuberans; gastrointestinal stromal tumors.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival | January 1, 2012 to January 10, 2020 | Overall survival was the duration from diagnosis of disease to death. |
| Event Free Survival | January 1, 2012 to January 10, 2020 | Time from the treatment initiation date to the date of treatment failure (TF), relapse from CR or better, or death from any cause, whichever comes first |
| Relapse Free Survival | January 1, 2012 to January 10, 2020 | Time from the treatment initiation date to the date of a relapse event, or death from any cause, whichever comes first |
| Best response | January 1, 2012 to January 10, 2020 | Best response recorded from treatment start until disease progression/recurrence |
| Time to best response | January 1, 2012 to January 10, 2020 | Time from treatment initiation until best response recorded |
| Duration of best response | January 1, 2012 to January 10, 2020 | Time from best response achieved until lose of response or the end of the record, whichever occurs first |
Outcome results
None listed